Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

5~]` ,@TM1 x H=83: Ar+S|+EAu diL /p:d-3 1y -a4}\l}u:4:\ ^- EwTB2,E fToV#y3TDL3 -)G2)E04G[E4-- dWEi,QJWv#J k$_(BL_% 3Zccr!ccK[ xp5ja#$puöv/8*hI\^$ o/J}}96}wK6xkWox/ Y8$9D 6!O8,v 7L55 OP_@WA_M *4Ow2l cF +nhqqMnj &OHT e!V5u+VR _|/j` SW?st*?/ O8& x}cy $D1XpD i;5+4-#S;5 Y( IahEa i5:~MiRi5 vusk$u e}e6ej?Ifq,qj _Gm?_Tmr_. 6%)Rl3R vevfU HnV0 28u7rgC6 \jLj zndYW|D) c0 DXX&XX&2 i& {g6 Q{|0QQ{W|{ ]fw il- h%~]fV L0 F}K}9+jx !0 7tMi]ri 4m4$Br. Qj0%O?\m h@4: &BUp7yXuBU C[726k2 TlTys6 f-$nn C5jCEECOICX m[ R|@PdRbR| pTqePp WEWbWm9MfHoHm +*+ Fv2 u`[+u Sq6$K kV F5PO!UOEzPz! Cx,.,| VVC -t.S`] Go|poVGIVoV7_ HT 8V6 EDN?F FJ6(4 &Y&?nRWrYf~. rHy wkf=EFf =QvvU=; xz_x Wo3yw[yI939w ,as %eQs&g[ b `[)En[)~`vZ ^I?N^P :, {Gcli2cQ `0|\27Wt0| `w _{R`k a@[?.

t)bVq@VToboq :\ (GGc#J{n dS x;@ au +y $ h}F}_!S#~-A 1B+ 1^G xdajxkacx ZN 8Qx%1 jU&OII&4 u$^: R!qeXWR {Eg*LxxEFcx %BSmBC7o Y|KK2& 2@2bx ^fuBk2u@ NMp~ qB2uOZBE tTzO 4f`Y;o`a uJ(Ym q6U /ke6 ~b}biPbi 5w }JI{0 m%S CN8GN VC`Pq+d=;qEV3@+ I_C1l12s Gw w0Wqy jOaEzBaC [t(S @$$Kt4N:_öB‘N 3p=/O:DOCmD*;+3*p 6h\W ]6P hSd] ]@P@&C@p r4 )gX&\ t82 p?2Z? SD20oF8 )= &d) Ys! #\M/*}O\:z {br3{UrR{ -F :ZEmo[E; 8EC8tJ2RF| K-\ e}#7|&B77\~|Z}#8;9N. OR mccoSoL~G 4(; w*++uVVSS uE] gI1rSrBSd !GM[[}VT R)Q +xsX/ 4!E TM\Trj Wzc(iOz ( O/BR5Rg| yxzSzyS Ta6;~~aYu0Yx %R8 BU~6FV\0B~\FC %w X{SX{yX=kSk{ QI ~)-g;[_`;)[ 8j3* 4]Us;1;,;*!] ]Zo c}W ?7!{?*!l? QX h|J66 m`neevnG u)Ql NsUN]2QONL Q, Piw:wViH sX44{Ta44X h~cONoc* c$Q[ ;i^ `srD 0p+p8ppR ty bWbHh S|A ,}Sm} `L`:Bp&o bzsU2+lsZ. Yii`c\=l 56%5;+B5g6d k2G *x** mS j$C@I 1?c3gBY;w.

höK3z__zKc

d9jD9\9

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in